Latest Insider Transactions at Lexicon Pharmaceuticals, Inc. (LXRX)
This section provides a real-time view of insider transactions for Lexicon Pharmaceuticals, Inc. (LXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LEXICON PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LEXICON PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2023
|
Kristen Alexander VP, Finance and Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
5,330
-14.94%
|
$10,660
$2.17 P/Share
|
|
Feb 28
2023
|
Kristen Alexander VP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
18,717
+17.37%
|
-
|
|
Feb 28
2023
|
Jeffrey L Wade President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,255
-11.1%
|
$60,510
$2.17 P/Share
|
|
Feb 28
2023
|
Jeffrey L Wade President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
78,916
+9.51%
|
-
|
|
Feb 28
2023
|
Brian T Crum SVP, General Counsel & Secr. |
SELL
Payment of exercise price or tax liability
|
Direct |
20,537
-13.22%
|
$41,074
$2.17 P/Share
|
|
Feb 28
2023
|
Brian T Crum SVP, General Counsel & Secr. |
BUY
Exercise of conversion of derivative security
|
Direct |
55,877
+11.86%
|
-
|
|
Feb 28
2023
|
Craig B Granowitz SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,732
-45.61%
|
$25,464
$2.17 P/Share
|
|
Feb 28
2023
|
Craig B Granowitz SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,917
+50.0%
|
-
|
|
Feb 28
2023
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
SELL
Payment of exercise price or tax liability
|
Direct |
19,118
-13.78%
|
$38,236
$2.17 P/Share
|
|
Feb 28
2023
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
BUY
Exercise of conversion of derivative security
|
Direct |
52,886
+12.49%
|
-
|
|
Feb 28
2023
|
Alan J Main EVP, Innov & Chem Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
20,946
-8.97%
|
$41,892
$2.17 P/Share
|
|
Feb 28
2023
|
Alan J Main EVP, Innov & Chem Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
57,943
+8.18%
|
-
|
|
Feb 28
2023
|
Lonnel Coats Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,971
-6.41%
|
$101,942
$2.17 P/Share
|
|
Feb 28
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209,327
+8.68%
|
-
|
|
Aug 05
2022
|
Artal International S.C.A. |
BUY
Open market or private purchase
|
Indirect |
2,426,070
+4.55%
|
$4,852,140
$2.5 P/Share
|
|
Aug 05
2022
|
Invus Us Partners LLC Director |
BUY
Open market or private purchase
|
Indirect |
147,390
+2.63%
|
$294,780
$2.5 P/Share
|
|
Aug 01
2022
|
Raymond Debbane Director |
BUY
Open market or private purchase
|
Indirect |
982,600
+15.63%
|
$1,965,200
$2.5 P/Share
|
|
Aug 01
2022
|
Invus Us Partners LLC Director |
BUY
Open market or private purchase
|
Indirect |
982,600
+15.63%
|
$1,965,200
$2.5 P/Share
|
|
Aug 01
2022
|
Artal International S.C.A. |
BUY
Open market or private purchase
|
Indirect |
16,173,800
+25.03%
|
$32,347,600
$2.5 P/Share
|
|
Apr 30
2022
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Apr 30
2022
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+5.41%
|
-
|
|
Apr 30
2022
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+1.2%
|
-
|
|
Apr 30
2022
|
Robert J Md Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Apr 30
2022
|
Alan S Nies Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.25%
|
-
|
|
Apr 30
2022
|
Frank Palantoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Apr 30
2022
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+2.62%
|
-
|
|
Apr 30
2022
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Feb 28
2022
|
Lonnel Coats Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
48,053
-7.58%
|
$96,106
$2.85 P/Share
|
|
Feb 28
2022
|
Lonnel Coats Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
197,343
+10.22%
|
-
|
|
Feb 28
2022
|
Jeffrey L Wade President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
25,773
-11.74%
|
$51,546
$2.85 P/Share
|
|
Feb 28
2022
|
Jeffrey L Wade President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
66,933
+10.02%
|
-
|
|
Feb 28
2022
|
Brian T Crum SVP, General Counsel & Secr. |
SELL
Payment of exercise price or tax liability
|
Direct |
15,059
-13.15%
|
$30,118
$2.85 P/Share
|
|
Feb 28
2022
|
Brian T Crum SVP, General Counsel & Secr. |
BUY
Exercise of conversion of derivative security
|
Direct |
40,880
+11.76%
|
-
|
|
Feb 28
2022
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
SELL
Payment of exercise price or tax liability
|
Direct |
13,241
-13.36%
|
$26,482
$2.85 P/Share
|
|
Feb 28
2022
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
BUY
Exercise of conversion of derivative security
|
Direct |
36,628
+12.17%
|
-
|
|
Feb 28
2022
|
Alan J Main EVP, Innov & Chem Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
19,756
-10.11%
|
$39,512
$2.85 P/Share
|
|
Feb 28
2022
|
Alan J Main EVP, Innov & Chem Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
54,650
+9.19%
|
-
|
|
Feb 28
2022
|
Kiernan Seth VP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,261
-27.42%
|
$16,522
$2.85 P/Share
|
|
Feb 28
2022
|
Kiernan Seth VP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,128
+34.11%
|
-
|
|
Feb 28
2022
|
Kristen Alexander VP, Finance and Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
3,337
-16.44%
|
$6,674
$2.85 P/Share
|
|
Feb 28
2022
|
Kristen Alexander VP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
11,300
+18.67%
|
-
|
|
Apr 24
2021
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+28.26%
|
-
|
|
Apr 24
2021
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+13.83%
|
-
|
|
Apr 24
2021
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+3.15%
|
-
|
|
Apr 24
2021
|
Robert J Md Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+28.26%
|
-
|
|
Apr 24
2021
|
Alan S Nies Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+27.73%
|
-
|
|
Apr 24
2021
|
Frank Palantoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+28.26%
|
-
|
|
Apr 24
2021
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+6.57%
|
-
|
|
Apr 24
2021
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,638
+28.26%
|
-
|
|
Mar 15
2021
|
James F Tessmer VP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
22,912
-13.76%
|
$137,472
$6.91 P/Share
|